YAP1 and nonpapillary renal cell carcinoma: Since YAP and TAZ are activated in various forms of renal cancer (e.g., ccRCC), additional studies are necessary to further investigate disease-specific or context-specific (e.g., onset or late-stage) effects of Hippo nuclear effector activation to oncogenesis.